Does DACTOLISIB Cause Malignant neoplasm progression? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Malignant neoplasm progression have been filed in association with DACTOLISIB. This represents 33.3% of all adverse event reports for DACTOLISIB.
6
Reports of Malignant neoplasm progression with DACTOLISIB
33.3%
of all DACTOLISIB reports
0
Deaths
5
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DACTOLISIB?
Of the 6 reports, 5 (83.3%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DACTOLISIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does DACTOLISIB Cause?
Diarrhoea (10)
Nausea (9)
Vomiting (8)
Headache (7)
Hepatic pain (6)
Lethargy (6)
Pancreatic neuroendocrine tumour (6)
Therapy non-responder (6)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)